TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22340282

Group type: EXPERIMENTAL
Intervention: ALA-PDT (20% solution of ALA applied for 1 hour, two sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Imiquimod 5% cream (half a sachet applied twice weekly)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 61

Group type: COMPARATOR
Intervention: Imiquimod 5% cream
Number of subjects: 61
Study: 20441691

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 785
Study: 17276575

Group type: EXPERIMENTAL
Intervention: Resuscitation in a flying helicopter
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Resuscitation in a moving ambulance
Number of subjects: 11

Group type: COMPARATOR
Intervention: Resuscitation at the scene
Number of subjects: 11
Study: 15934987

Group type: EXPERIMENTAL
Intervention: PLTs pooled before storage
Number of subjects: 23

Group type: COMPARATOR
Intervention: PLTs stored individually
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pooled storage
Number of subjects: 23

Group type: COMPARATOR
Intervention: Routine storage
Number of subjects: 23
Study: 12000378

Group type: EXPERIMENTAL
Intervention: Terbinafine for 6 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Terbinafine for 8 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Griseofulvin (20 mg x kg(‐1) x day(‐1)) for 12 weeks
Number of subjects: 134
Study: 9549823

Group type: EXPERIMENTAL
Intervention: Complete case analysis (MCAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-effects models (MAR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint mixed-effects and survival model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pattern-mixture model
Number of subjects: 0
Study: 7789675

Group type: EXPERIMENTAL
Intervention: Polyvinyl bougies (Savary type)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Through-the-scope balloons
Number of subjects: 34
Study: 2281807

Group type: EXPERIMENTAL
Intervention: Fengabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study: 6802779

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB) at doses ranging from 0.5 to 1.5 mg/kg/day and from 1.6 to 2.5 mg/kg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low doses of Phenobarbital (PB)
Number of subjects: 90
Study: 31642352

Group type: EXPERIMENTAL
Intervention: High-dose exercise training (1-hour sessions, 3 times weekly for 12 weeks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Low-dose exercise training (1-hour sessions, 2 times weekly for 8 weeks)
Number of subjects: 164
Study: 30992293

Group type: EXPERIMENTAL
Intervention: Brief support (HP-led 10 min consultation and written self-help guide)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Brief support plus shopping feedback (same HP-led support plus personalized feedback based on grocery store loyalty card data)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 112
Study: 28515107

Group type: EXPERIMENTAL
Intervention: 1,000 IU/day vitamin D3
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: 2,000 IU/day vitamin D3
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: 3,000 IU/day vitamin D3
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 25894912

Group type: EXPERIMENTAL
Intervention: TaperGuard ETT (group T)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional ETT (group C)
Number of subjects: 58
Study: 23945130

Group type: EXPERIMENTAL
Intervention: SP-IPT (25 mg of sulfadoxine and 1.25 mg of pyrimethamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily co-trimoxazole doses (960 mg per dose)
Number of subjects: 0
Study: 21860922

Group type: EXPERIMENTAL
Intervention: Essential oils (EOs) mouthrinse
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 142

Group type: COMPARATOR
Intervention: Negative control rinse
Number of subjects: 142
Study: 19487941

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intravenous amiodarone
Number of subjects: 150
Study: 16718797

Group type: EXPERIMENTAL
Intervention: One-day quadruple therapy (omeprazole 20 mg, amoxicillin 1 g, furazolidone 200 mg, colloidal bismuth subcitrate 220 mg four times for one day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Seven-day triple therapy (omeprazole 40 mg, amoxycillin 1 g, furazolidone 100 mg, all twice a day for 7 days)
Number of subjects: 60
Study: 15310638

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 30 microg
Number of subjects: 50
Study: 11318078

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gel-forming solution (timolol GS) once daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: 0.5% timolol solution twice daily
Number of subjects: 286
Study: 9542556

Group type: EXPERIMENTAL
Intervention: Epidural tramadol 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Epidural tramadol 100 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8138772

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3581680

Group type: EXPERIMENTAL
Intervention: Pilocarpine and carbacholine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combination of atropine and pilocarpine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atropine, scopolamine, metacine or chlorosyle (inducing 'paradoxical' salivation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Spontaneous secretion
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reflex secretion (partially restored)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Denervated glands
Number of subjects: 22
Study: 30525740

Group type: EXPERIMENTAL
Intervention: 1.8% self-prepared hypertonic nasal saline irrigation (1.8% SPHNSI)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 0.9% commercial isotonic nasal saline irrigation (0.9% CINSI)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 1.8% SPHNSI and 0.9% CINSI
Number of subjects: 78
Study: 29729169

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 polyunsaturated fatty acids) 2 capsules (1680 mg) for one month along with standard treatment
Number of subjects: 90
Study: 27566551

Group type: EXPERIMENTAL
Intervention: Deep sea fish oil (0.2 ml/Kg bodyweight/day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Corn oil (0.2 ml/Kg bodyweight/day)
Number of subjects: 77
Study: 26599957

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 30
Study: 22423115

Group type: EXPERIMENTAL
Intervention: Line drawings of tools as prime stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-elongated tool pictures as prime stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elongated stick-like rectangles as prime stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elongated vegetables as prime stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stubby vegetables as prime stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotated elongated stick-like rectangles, diamond shapes, and cut circles as prime stimuli
Number of subjects: 0
Study: 21086592

Group type: EXPERIMENTAL
Intervention: Mesotherapy (MT) and Electro-stimulation (EMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 18242486

Group type: EXPERIMENTAL
Intervention: Stress-rest sestamibi SPECT imaging with physical exercise (n = 573)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Stress-rest sestamibi SPECT imaging with dipyridamole (n = 433)
Number of subjects: 1006
Study: 15951544

Group type: EXPERIMENTAL
Intervention: Retarded release phosphatidylcholine (6 g daily for three months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12034943

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 430

Group type: COMPARATOR
Intervention: Arthroscopy
Number of subjects: 430
Study: 10505588

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 7558547

Group type: EXPERIMENTAL
Intervention: Preparation of living wills in the treatment group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Preparation of living wills in the control group
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Life-sustaining treatment decisions in the treatment group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Life-sustaining treatment decisions in the control group
Number of subjects: 200
Study: 1782304

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg orally
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 358369

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Selective vagotomy with pyloroplasty (SV +P)
Number of subjects: 50
Study: 31701378

Group type: EXPERIMENTAL
Intervention: Vignettes about women with underweight BMI
Number of subjects: 295

Group type: COMPARATOR
Intervention: Vignettes about women with average weight BMI
Number of subjects: 295

Group type: COMPARATOR
Intervention: Vignettes about women with overweight BMI
Number of subjects: 295
Study: 31221221

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 437

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study: 28101565

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation + conventional physical therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional group (sham neuromuscular electrical stimulation + conventional physical therapy)
Number of subjects: 25
Study: 26468173

Group type: EXPERIMENTAL
Intervention: Isometric massage in Group A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group B) without isometric massage
Number of subjects: 40
Study: 23813878

Group type: EXPERIMENTAL
Intervention: PACI‐O (Personal Aspirations and Concerns Inventory for Offenders)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no PACI‐O)
Number of subjects: 37
Study: 20718944

Group type: EXPERIMENTAL
Intervention: Δ(9) ‐THC (10 mg in IBS patients, 5 and 10 mg in healthy volunteers)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19794261

Group type: EXPERIMENTAL
Intervention: Soybean isoflavones
Number of subjects: 0
Study: 17096160

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (Hfx) RTx with concurrent TPF CTx
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional fractionation (Cfx) RTx with concurrent TPF CTx
Number of subjects: 50
Study: 15190136

Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: 1.25 mg of droperidol
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: Nitrogen
Number of subjects: 5199

Group type: COMPARATOR
Intervention: Volatile anesthetic
Number of subjects: 5199

Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 5199

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 5199

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 5199
Study: 11296071

Group type: EXPERIMENTAL
Intervention: Holistic medicine consultations for oncology patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Holistic medicine consultations for symptom management
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Questions about specific therapies
Number of subjects: 70
Study: 9488591

Group type: EXPERIMENTAL
Intervention: Oral beta-carotene
Number of subjects: 1805

Group type: COMPARATOR
Intervention: History of one or more previous SCCs
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Multiple prior BCCs
Number of subjects: 1805

Group type: COMPARATOR
Intervention: Previous SCC or multiple BCC
Number of subjects: 1805
Study: 8157190

Group type: EXPERIMENTAL
Intervention: Cisplatin (regimen A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cisplatin with 5-FU infusion (regimen B)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both regimens A and B
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with cisplatin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Entire group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with microscopic metastasis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with macroscopic metastasis
Number of subjects: 17
Study: 3047855

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 136
Study: 30144995

Group type: EXPERIMENTAL
Intervention: LVEF < 25%
Number of subjects: 19740

Group type: COMPARATOR
Intervention: LVEF > 35%
Number of subjects: 19740
Study: 27979724

Group type: EXPERIMENTAL
Intervention: NEJM video
Number of subjects: 30

Group type: COMPARATOR
Intervention: Didactic teaching session
Number of subjects: 30
Study: 25527767

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 56
Study: 23949277

Group type: EXPERIMENTAL
Intervention: Home-based technologies coupled with teleassistance service (HBTec-TS)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No home-based technologies (control group)
Number of subjects: 96
Study: 21248359

Group type: EXPERIMENTAL
Intervention: Living cellular constructs (LCC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Autogenous free gingival grafts
Number of subjects: 44
Study: 18282805

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 305

Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 305
Study: 17408818

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb aerosol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schwarz subcutaneous
Number of subjects: 0

Group type: COMPARATOR
Intervention: Edmonston-Zagreb subcutaneous
Number of subjects: 0
Study: 15131566

Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine (4%, 100 mg) 4 times daily for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline) 4 times daily for 8 weeks
Number of subjects: 50
Study: 11176555

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil questionnaire administration
Number of subjects: 134

Group type: COMPARATOR
Intervention: Computer administration
Number of subjects: 134
Study: 9023171

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 325

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 325
Study: 7932392

Group type: EXPERIMENTAL
Intervention: Dilute vasopressin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 3124478

Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid treatment for 3 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated similar patients
Number of subjects: 17
Study: 30880747

Group type: EXPERIMENTAL
Intervention: NACCRT (Neoadjuvant Concurrent Chemoradiotherapy)
Number of subjects: 39
Study: 28201598

Group type: EXPERIMENTAL
Intervention: TransCon GH (0.14 mg GH/kg/wk)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TransCon GH (0.21 mg GH/kg/wk)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TransCon GH (0.30 mg GH/kg/wk)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Genotropin (0.03 mg GH/kg/d)
Number of subjects: 53
Study: 25840599

Group type: EXPERIMENTAL
Intervention: sirolimus/tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate/tacrolimus
Number of subjects: 0
Study: 24412161

Group type: EXPERIMENTAL
Intervention: Early coronary angiography
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Coronary reperfusion
Number of subjects: 3981

Group type: EXPERIMENTAL
Intervention: Induced hypothermia
Number of subjects: 3981
Study: 23208159

Group type: EXPERIMENTAL
Intervention: Weight-loss diet (WL) with caloric restriction of 500 kcal/day for 16 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Weight-loss diet plus resistance training (WL+RT) with caloric restriction of 500 kcal/day and 16-week resistance training (2 sessions per week)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 34
Study: 19015206

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg every 4 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 17468442

Group type: EXPERIMENTAL
Intervention: Magnetization transfer imaging (MTR) in affected optic nerves
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Visual evoked potential (VEP) latency measurements
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lesion-only MTR measurements
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) for retinal neuroaxonal loss
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (15 controls)
Number of subjects: 25
Study: 15947332

Group type: EXPERIMENTAL
Intervention: GM‐CSF (125 microg/m2) for 72 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12034158

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg bid)
Number of subjects: 3029

Group type: COMPARATOR
Intervention: Metoprolol (50 mg bid)
Number of subjects: 3029
Study: 11913407

Group type: EXPERIMENTAL
Intervention: CE + MPA 2.5 mg
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: CE + MPA 5 mg
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: CE + MPA 5 mg (last 14 cycle days)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: CE + MPA 10 mg (last 14 cycle days)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Unopposed CE regimen
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo (matching tablets)
Number of subjects: 525
Study: 7986853

Group type: EXPERIMENTAL
Intervention: LCT group (45% caloric intake from LCT 20% emulsion)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: MCT group (45% caloric intake from physical mixture of LCT and MCT at 20% concentration)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (without lipids, all caloric intake from hypertonic glucose solution)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both lipid emulsions (LCT and MCT)
Number of subjects: 21
Study: 3142775

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg twice daily for 4 weeks)
Number of subjects: 18
Study: 31150711

Group type: EXPERIMENTAL
Intervention: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules (DMR)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Topical ivermectin 1% cream and placebo
Number of subjects: 273
Study: 29587698

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional Care Management (Control)
Number of subjects: 250
Study: 27999853

Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 208

Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 208
Study: 26210844

Group type: EXPERIMENTAL
Intervention: RITA-T (Rapid Interactive Screening Test for Autism in Toddlers)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: RITA-T
Number of subjects: 61
Study: 23117026

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21359174

Group type: EXPERIMENTAL
Intervention: Smaller weight at birth
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low birth weight for placental weight
Number of subjects: 140
Study: 18927312

Group type: EXPERIMENTAL
Intervention: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Number of subjects: 255

Group type: COMPARATOR
Intervention: IV Bisphosphonate (open-label)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 255

Group type: COMPARATOR
Intervention: IV Bisphosphonate
Number of subjects: 255

Group type: COMPARATOR
Intervention: Denosumab and IV Bisphosphonate
Number of subjects: 255
Study: 16330868

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy and hypothermia (HH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hemicraniectomy alone (HA)
Number of subjects: 25
Study: 12859265

Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine hydrochloride
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac tromethamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (for olopatadine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (for ketorolac)
Number of subjects: 40
Study: 11055129

Group type: EXPERIMENTAL
Intervention: 1-stage sinus inlay bone grafts
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2-stage sinus inlay bone grafts
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-grafted areas
Number of subjects: 40
Study: 8638357

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg three times daily
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Flutamide 125 mg twice daily
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg once daily
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice daily
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Flutamide (all doses)
Number of subjects: 372
Study: 1602504

Group type: EXPERIMENTAL
Intervention: Single oral dose of 3.5 g ampicillin plus 1 g probenecid
Number of subjects: 202

Group type: COMPARATOR
Intervention: 500 mg ampicillin orally four times a day for 10 days
Number of subjects: 202
Study: 6442211

Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 155
Study: 29720327

Group type: EXPERIMENTAL
Intervention: occlusal splint (MOS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: clear aligners (CAT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo splint (PMS)
Number of subjects: 60
Study: 26656481

Group type: EXPERIMENTAL
Intervention: Low-poverty neighborhoods intervention
Number of subjects: 1550